Hung Q Ly

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11299049/publications.pdf

Version: 2024-02-01

394421 377865 1,172 42 19 34 citations h-index g-index papers 42 42 42 2032 all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Contrast-Induced Nephropathy: From Pathophysiology to Preventive Strategies. Canadian Journal of Cardiology, 2016, 32, 247-255.	1.7	206
2	Epidemiology, Management Strategies, and Outcomes of Patients With Chronic Total Coronary Occlusion. American Journal of Cardiology, 2016, 118, 1128-1135.	1.6	106
3	Initial Findings From the North American COVID-19 Myocardial Infarction Registry. Journal of the American College of Cardiology, 2021, 77, 1994-2003.	2.8	96
4	Association of Platelet Counts on Presentation and Clinical Outcomes in ST-Elevation Myocardial Infarction (from the TIMI Trials). American Journal of Cardiology, 2006, 98, 1-5.	1.6	73
5	A pilot study: The Noninvasive Surface Cooling Thermoregulatory System for Mild Hypothermia Induction in Acute Myocardial Infarction (The NICAMI Study). American Heart Journal, 2005, 150, 933.e9-933.e13.	2.7	71
6	Precautions and Procedures for Coronary and Structural Cardiac Interventions During the COVID-19 Pandemic: Guidance from Canadian Association of Interventional Cardiology. Canadian Journal of Cardiology, 2020, 36, 780-783.	1.7	61
7	In Vivo Tracking in Cardiac Stem Cell-Based Therapy. Progress in Cardiovascular Diseases, 2007, 49, 414-420.	3.1	56
8	Mesenchymal stem cell mediates cardiac repair through autocrine, paracrine and endocrine axes. Journal of Translational Medicine, 2020, 18, 336.	4.4	55
9	In vivo myocardial distribution of multipotent progenitor cells following intracoronary delivery in a swine model of myocardial infarction. European Heart Journal, 2009, 30, 2861-2868.	2.2	42
10	Stem Cells Are Not Proarrhythmic: Letting the Genie out of the Bottle. Circulation, 2009, 119, 1824-1831.	1.6	39
11	The Paracrine Effect: Pivotal Mechanism in Cell-Based Cardiac Repair. Journal of Cardiovascular Translational Research, 2010, 3, 652-662.	2.4	34
12	North American COVID-19 ST-Segment-Elevation Myocardial Infarction (NACMI) registry: Rationale, design, and implications. American Heart Journal, 2020, 227, 11-18.	2.7	33
13	The effect of bromocriptine on left ventricular functional recovery in peripartum cardiomyopathy: insights from the <scp>BROâ€HF</scp> retrospective cohort study. ESC Heart Failure, 2019, 6, 27-36.	3.1	30
14	Association Between Adherence to Fractional Flow Reserve Treatment Thresholds and Major Adverse Cardiac Events in Patients With Coronary Artery Disease. JAMA - Journal of the American Medical Association, 2020, 324, 2406.	7.4	30
15	Imaging in cardiac cell-based therapy: in vivo tracking of the biological fate of therapeutic cells. Nature Clinical Practice Cardiovascular Medicine, 2008, 5, S96-S102.	3.3	29
16	Direct Stenting Versus Preâ€Dilation in STâ€Elevation Myocardial Infarction: A Systematic Review and Metaâ€Analysis. Journal of Interventional Cardiology, 2015, 28, 119-131.	1.2	26
17	Prognostic impact of the residual <scp>SYNTAX</scp> score on inâ€hospital outcomes in patients undergoing primary percutaneous coronary intervention. Catheterization and Cardiovascular Interventions, 2016, 88, 740-747.	1.7	22
18	Angiographic and clinical outcomes associated with direct versus conventional stenting among patients treated with fibrinolytic therapy for ST-elevation acute myocardial infarction. American Journal of Cardiology, 2005, 95, 383-386.	1.6	21

#	Article	IF	CITATIONS
19	Procedural and Long-Term Outcomes of Bioresorbable Scaffolds Versus Drug-Eluting Stents in Chronic Total Occlusions. Circulation: Cardiovascular Interventions, 2016, 9, .	3.9	20
20	Effect of Radial-to-Femoral Access Crossover on Adverse Outcomes in Primary Percutaneous Coronary Intervention. American Journal of Cardiology, 2014, 114, 1165-1173.	1.6	15
21	Sudden death and hypertrophic cardiomyopathy: a review. Canadian Journal of Cardiology, 2005, 21, 441-8.	1.7	15
22	Weather and risk of ST-elevation myocardial infarction revisited: Impact on young women. PLoS ONE, 2018, 13, e0195602.	2.5	12
23	Transradial Percutaneous Coronary Interventions in Acute Coronary Syndrome. American Journal of Cardiology, 2014, 114, 160-168.	1.6	11
24	Advances in Gene-Based Therapy for Heart Failure. Journal of Cardiovascular Translational Research, 2008, 1, 127-136.	2.4	9
25	Bioresorbable Vascular Scaffold During ST-Elevation Myocardial Infarction: A Systematic Review. Canadian Journal of Cardiology, 2017, 33, 515-524.	1.7	9
26	Impact of summer season on pre-hospital time delays in women and men undergoing primary percutaneous coronary intervention. Science of the Total Environment, 2019, 656, 322-330.	8.0	8
27	Surgical Turndown: "What's in a Name?―for Patients Deemed Ineligible for Surgical Revascularization. Canadian Journal of Cardiology, 2019, 35, 959-966.	1.7	7
28	Collectively Operated Fellow-Initiated Research as a Novel Teaching Model to Bolster Interest and Increase Proficiency in Academic Research. Canadian Journal of Cardiology, 2017, 33, 685-687.	1.7	6
29	Development of Acute Myocardial Infarction Mortality and Readmission Models for Public Reporting on Hospital Performance in Canada. CJC Open, 2021, 3, 1051-1059.	1.5	6
30	Novel Artificial Intelligence Applications in Cardiology: Current Landscape, Limitations, and the Road to Real-World Applications. Journal of Cardiovascular Translational Research, 2023, 16, 513-525.	2.4	5
31	Fractional flow reserve and resting indices for coronary physiologic assessment: Practical guide, tips, and tricks. Catheterization and Cardiovascular Interventions, 2017, 90, 598-611.	1.7	4
32	When the Complex Meets the High-Risk: Mechanical Cardiac Support Devices and Percutaneous Coronary Interventions in Severe Coronary Artery Disease. Canadian Journal of Cardiology, 2020, 36, 270-279.	1.7	4
33	Everolimusâ€eluting bioresorbable vascular scaffold implantation to treat saphenous vein graft disease, singleâ€center initial experience. Journal of Interventional Cardiology, 2017, 30, 433-439.	1.2	3
34	Hockey Games and the Incidence of ST-Elevation Myocardial Infarction. Canadian Journal of Cardiology, 2018, 34, 744-751.	1.7	3
35	Clinical outcomes of bioresorbable vascular scaffold to treat all-comer patients. Are patients with acute coronary syndrome better candidates for bioresorbable vascular scaffold?. Cardiovascular Revascularization Medicine, 2019, 20, 228-234.	0.8	2
36	230. In Vivo Fluorescence Tracking System for Cardiac Stem Cell Therapy. Molecular Therapy, 2006, 13, S88.	8.2	1

#	Article	IF	CITATIONS
37	Bioresorbable vascular scaffold to treat inâ€stent restenosis: Singleâ€center experience. Journal of Interventional Cardiology, 2017, 30, 558-563.	1.2	1
38	Long-term outcomes of bioresorbable vascular scaffold in ST-elevation myocardial infarction. Acta Cardiologica, 2018, 73, 276-281.	0.9	1
39	Nothing Refractory About Cardiac Cell Therapy. Canadian Journal of Cardiology, 2013, 29, 905-907.	1.7	O
40	Letter by Azzalini and Ly Regarding Article, "The Learning Curve for Transradial Percutaneous Coronary Intervention among Operators in the United States: A Study from the National Cardiovascular Data Registry― Circulation, 2015, 131, e357.	1.6	0
41	Letter by Picard and Ly Regarding Article, "Frequency and Predictors of Internal Mammary Artery Graft Failure and Subsequent Clinical Outcomes: Insights From the Project of Ex-Vivo Vein Graft Engineering via Transfection (PREVENT) IV Trial― Circulation, 2016, 133, e663.	1.6	0
42	Giant aneurysm of a saphenous vein graft causing compression of cardiac structures in a patient with lung tumour: who is doing what?. European Heart Journal Cardiovascular Imaging, 2017, 18, 113-113.	1.2	0